CBD - Revision history

Lazy at 08:19, 18 January 2025

2025-01-18T08:19:02Z

← Older revision		Revision as of 01:19, 18 January 2025
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=~~CBD~~ (~~Cannabidiol~~)		\|drug_name=Sodium R Lipoate and Hydroxycitrate (METABLOC)
	\|~~overview~~=~~CBD is a non-psychoactive component of cannabis. It has shown potential therapeutic effects~~ in ~~cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects.~~		\|FDA_approval=No (Used in investigational metabolic therapy for brain tumors)
	~~\|FDA_approval=Yes,~~ for ~~specific epilepsy syndromes; not FDA-approved for cancer treatment~~		\|used_for=Investigational use in brain tumor treatment, including primary and metastatic gliomas
	\|used_for=Investigational use in ~~cancer~~ treatment, including ~~symptom management~~ and ~~potential anti-tumor effects~~		\|clinical_trial_phase=Early clinical evaluation in a small case series
	\|clinical_trial_phase=~~Preclinical studies and early human trials for cancer~~		\|common_side_effects=Not specified in the provided information
	\|common_side_effects=~~Tiredness, diarrhea, changes~~ in ~~appetite/weight; generally well-tolerated at doses used for epilepsy~~		\|OS_with=Varies; one GBM patient had a significant tumor shrinkage, others showed extended progression-free survival, including one patient surviving 87 months post-diagnosis
	\|OS_with=~~Not applicable~~; ~~ongoing research into potential impacts on overall~~ survival ~~in cancer patients~~		\|PFS_with=Majority of newly diagnosed patients without disease progression for periods extending to 2-3 years, and in one case, 87 months
	\|PFS_with=~~Not applicable; ongoing research into potential impacts on~~ progression-~~free~~ survival in ~~cancer~~ patients		\|usefulness_rating=3
	\|~~usefulness_rating~~=4		\|notes=This metabolic therapy, combining sodium R lipoate and hydroxycitrate, has shown promising outcomes in a small French study involving glioma patients. The therapy aims to disrupt cancer metabolism, potentially extending survival and reducing tumor size in some patients. While preliminary results are encouraging, particularly for patients with newly diagnosed gliomas, the need for well-conducted, larger-scale trials is emphasized to firmly establish efficacy and safety.
			\|treatment_category=Over-the-Counter Drugs and Supplements
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	~~\|treatment_category=Nutraceuticals~~		\|toxicity_explanation=The toxicity of Sodium R Lipoate and Hydroxycitrate (METABLOC) has been assessed as relatively low. It's still undergoing early clinical evaluation, which means it hasn't caused any severe adverse reactions to this point. However, we lack specific information on its common side effects. It's important to remember that everybody's body responds differently to medications, so while the toxicity appears low, some individuals may still experience side effects.
	\|toxicity_explanation=The toxicity ~~level~~ of ~~CBD~~ (~~Cannabidiol~~) is relatively low. It's ~~been reported~~ to ~~be generally well-tolerated, especially at doses used for epilepsy~~. ~~Typically~~, side effects ~~may include tiredness, diarrhea, and changes in appetite or weight~~. ~~However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific~~ to ~~cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It~~'s ~~essential~~ to ~~discuss with your healthcare provider before starting any new treatment regimen~~.		\|overview=Sodium R Lipoate and Hydroxycitrate (METABLOC) is an investigational metabolic therapy for brain tumors, particularly gliomas, showing promising outcomes in early clinical evaluations, including significant tumor shrinkage and extended progression-free survival in some patients. While the therapy has a relatively low toxicity level and no severe adverse reactions reported thus far, further large-scale trials are needed to confirm its efficacy and safety.}}
	\|~~notes~~=~~CBD, a non-psychoactive component of cannabis, has been explored~~ for ~~its potential therapeutic effects in cancer treatment~~, ~~including anti-inflammatory~~, ~~analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown~~ promising ~~results~~, including ~~inhibition of~~ tumor ~~growth~~ and ~~synergistic effects with chemotherapy~~ in ~~models of glioblastoma and other cancers,~~
	~~conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment~~.

	~~=== Sativex (Nabiximols) and Glioblastoma ===~~
	~~A Phase 1b trial investigated~~ the ~~combination of Sativex (nabiximols),~~ a ~~cannabis-based spray containing a 1:1 ratio of CBD~~ and ~~THC~~, ~~with temozolomide (TMZ) chemotherapy in patients with recurrent glioblastoma. The study observed a significant improvement in one~~-year survival rates among patients treated with Sativex compared to the placebo group (83% versus 44%, respectively). This difference suggests that Sativex could enhance survival when combined with standard chemotherapy. However, researchers emphasize that these findings, while promising, need to be confirmed in larger, more robust clinical trials~~.<ref>{{Cite web \|title=Clinical Trial: CBD~~
	~~Doubles Brain Cancer Survival Rates \|url=https://mysupplyco.com \|publisher=My Supply Co. \|accessdate=2024-08-12}}</ref>~~

	~~=== Potential Mechanisms and Future Research ===~~
	~~The effects of CBD in glioblastoma~~ are ~~thought~~ to ~~stem from~~ its ability to inhibit tumor cell migration, invasion, and angiogenesis. CBD has shown potential in modulating the immune environment around the tumor, possibly enhancing the effectiveness of other treatments like chemotherapy. These preclinical findings, along with the initial clinical results, suggest a multi-targeted approach by CBD that could be beneficial in treating glioblastoma.<ref>{{Cite web \|title=From bench to bedside: the application of cannabidiol in glioma \|url=https://translational-medicine.biomedcentral.com \|publisher=Journal of Translational Medicine \|accessdate=2024-08-12}}</ref>

	~~Further research, including ongoing and future trials, is necessary to fully understand the impact of CBD and THC-based treatments on overall survival in glioblastoma patients~~ and ~~to determine the best protocols for their use~~.~~<ref>{{Cite web \|title=Developments in cannabis-based drug trial for glioblastomas \|url=https://www.thebraintumourcharity.org \|publisher=The Brain Tumour Charity \|accessdate=2024-08-12}}</ref>~~


	}}

Lazy at 20:49, 25 December 2024

2024-12-25T20:49:08Z

← Older revision		Revision as of 13:49, 25 December 2024
Line 9:		Line 9:
	\|PFS_with=Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients		\|PFS_with=Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients
	\|usefulness_rating=4		\|usefulness_rating=4
			\|links=
			\|toxicity_level=2
			\|treatment_category=Nutraceuticals
			\|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.
	\|notes=CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers,		\|notes=CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers,
	conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.		conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.
Line 22:		Line 26:


	~~\|links=~~
	~~\|toxicity_level=2~~
	~~\|treatment_category=Nutraceuticals~~
	\|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.
	}}		}}

Lazy at 20:47, 25 December 2024

2024-12-25T20:47:11Z

← Older revision		Revision as of 13:47, 25 December 2024
Line 22:		Line 22:


	~~\|treatment_category=Nutraceuticals~~
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
			\|treatment_category=Nutraceuticals
	\|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.		\|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.
	}}		}}

Lazy at 20:38, 25 December 2024

2024-12-25T20:38:24Z

← Older revision		Revision as of 13:38, 25 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=CBD (Cannabidiol)		\|drug_name=CBD (Cannabidiol)
	\| overview=CBD is a non-psychoactive component of cannabis. It has shown potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects.		\|overview=CBD is a non-psychoactive component of cannabis. It has shown potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects.
	\|FDA_approval=Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment		\|FDA_approval=Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment
	\|used_for=Investigational use in cancer treatment, including symptom management and potential anti-tumor effects		\|used_for=Investigational use in cancer treatment, including symptom management and potential anti-tumor effects

Lazy at 20:23, 25 December 2024

2024-12-25T20:23:55Z

← Older revision		Revision as of 13:23, 25 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=CBD (Cannabidiol)		\|drug_name=CBD (Cannabidiol)
			\| overview=CBD is a non-psychoactive component of cannabis. It has shown potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects.
	\|FDA_approval=Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment		\|FDA_approval=Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment
	\|used_for=Investigational use in cancer treatment, including symptom management and potential anti-tumor effects		\|used_for=Investigational use in cancer treatment, including symptom management and potential anti-tumor effects

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:27:57Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:27, 12 November 2024
Line 21:		Line 21:


	\|~~category~~=Nutraceuticals		\|treatment_category=Nutraceuticals
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.		\|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen.
	}}		}}

Lazy at 21:10, 12 August 2024

2024-08-12T21:10:40Z

← Older revision		Revision as of 14:10, 12 August 2024
Line 11:		Line 11:
	conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.		conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.

	~~Recent research into~~ the ~~use~~ of ~~CBD~~ (~~cannabidiol~~) ~~for treating glioblastoma in human clinical trials has shown promising results~~, ~~particularly in its potential impact on overall survival (OS). One study involved~~ a ~~Phase II trial with Sativex, an oral~~ spray containing ~~both~~ CBD and THC, ~~in combination~~ with chemotherapy ~~for~~ patients with recurrent glioblastoma. The ~~earlier Phase I trial suggested that this combination might extend~~ survival~~, leading~~ to the ~~larger Phase II trial~~. This ~~ongoing trial aims~~ to ~~provide~~ more ~~definitive evidence on whether the addition of Sativex can significantly improve overall survival rates~~.		=== Sativex (Nabiximols) and Glioblastoma ===
	* Source: [https://~~www~~.~~thebraintumourcharity~~.~~org/news/research~~-~~news/cannabis-based~~-~~drug-trial-developments-glioblastom~~/ ~~Developments in cannabis-based drug trial for glioblastomas] - The Brain Tumour Charity, 2021.~~		A Phase 1b trial investigated the combination of Sativex (nabiximols), a cannabis-based spray containing a 1:1 ratio of CBD and THC, with temozolomide (TMZ) chemotherapy in patients with recurrent glioblastoma. The study observed a significant improvement in one-year survival rates among patients treated with Sativex compared to the placebo group (83% versus 44%, respectively). This difference suggests that Sativex could enhance survival when combined with standard chemotherapy. However, researchers emphasize that these findings, while promising, need to be confirmed in larger, more robust clinical trials.<ref>{{Cite web \|title=Clinical Trial: CBD
			Doubles Brain Cancer Survival Rates \|url=https://mysupplyco.com \|publisher=My Supply Co. \|accessdate=2024-08-12}}</ref>

	~~Another trial involved Nabiximols (formerly known as Nabisol)~~, ~~another cannabis-based drug~~. ~~This trial focused on patients with glioblastoma and investigated~~ the ~~potential benefits~~ of ~~adding Nabiximols to~~ the ~~standard treatment regimen. Preliminary~~ results ~~indicated~~ that ~~some patients experienced an increase~~ in ~~overall survival, although further research is needed~~ to ~~confirm these findings.~~		=== Potential Mechanisms and Future Research ===
	* Source: [https://~~clinicaltrials~~.~~gov~~/~~ct2/show/NCT01812603 A Study~~ of ~~Nabiximols (Cannabis Based Medicine) as Adjuvant Therapy~~ to ~~Temozolomide~~ in ~~Recurrent Glioblastoma]~~ - ~~ClinicalTrials~~.~~gov, 2023~~.		The effects of CBD in glioblastoma are thought to stem from its ability to inhibit tumor cell migration, invasion, and angiogenesis. CBD has shown potential in modulating the immune environment around the tumor, possibly enhancing the effectiveness of other treatments like chemotherapy. These preclinical findings, along with the initial clinical results, suggest a multi-targeted approach by CBD that could be beneficial in treating glioblastoma.<ref>{{Cite web \|title=From bench to bedside: the application of cannabidiol in glioma \|url=https://translational-medicine.biomedcentral.com \|publisher=Journal of Translational Medicine \|accessdate=2024-08-12}}</ref>

			Further research, including ongoing and future trials, is necessary to fully understand the impact of CBD and THC-based treatments on overall survival in glioblastoma patients and to determine the best protocols for their use.<ref>{{Cite web \|title=Developments in cannabis-based drug trial for glioblastomas \|url=https://www.thebraintumourcharity.org \|publisher=The Brain Tumour Charity \|accessdate=2024-08-12}}</ref>

Lazy at 20:58, 12 August 2024

2024-08-12T20:58:27Z

← Older revision		Revision as of 13:58, 12 August 2024
Line 12:		Line 12:

	Recent research into the use of CBD (cannabidiol) for treating glioblastoma in human clinical trials has shown promising results, particularly in its potential impact on overall survival (OS). One study involved a Phase II trial with Sativex, an oral spray containing both CBD and THC, in combination with chemotherapy for patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, leading to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates.		Recent research into the use of CBD (cannabidiol) for treating glioblastoma in human clinical trials has shown promising results, particularly in its potential impact on overall survival (OS). One study involved a Phase II trial with Sativex, an oral spray containing both CBD and THC, in combination with chemotherapy for patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, leading to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates.
	* Source: [https://www.thebraintumourcharity.org/news/research-news/cannabis-based-drug-trial-developments-glioblastom/ Developments in cannabis-based drug trial for glioblastomas		* Source: [https://www.thebraintumourcharity.org/news/research-news/cannabis-based-drug-trial-developments-glioblastom/ Developments in cannabis-based drug trial for glioblastomas] - The Brain Tumour Charity, 2021.
	] - The Brain Tumour Charity, 2021.

	Another trial involved Nabiximols (formerly known as Nabisol), another cannabis-based drug. This trial focused on patients with glioblastoma and investigated the potential benefits of adding Nabiximols to the standard treatment regimen. Preliminary results indicated that some patients experienced an increase in overall survival, although further research is needed to confirm these findings.		Another trial involved Nabiximols (formerly known as Nabisol), another cannabis-based drug. This trial focused on patients with glioblastoma and investigated the potential benefits of adding Nabiximols to the standard treatment regimen. Preliminary results indicated that some patients experienced an increase in overall survival, although further research is needed to confirm these findings.

Lazy at 20:58, 12 August 2024

2024-08-12T20:58:03Z

← Older revision		Revision as of 13:58, 12 August 2024
Line 12:		Line 12:

	Recent research into the use of CBD (cannabidiol) for treating glioblastoma in human clinical trials has shown promising results, particularly in its potential impact on overall survival (OS). One study involved a Phase II trial with Sativex, an oral spray containing both CBD and THC, in combination with chemotherapy for patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, leading to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates.		Recent research into the use of CBD (cannabidiol) for treating glioblastoma in human clinical trials has shown promising results, particularly in its potential impact on overall survival (OS). One study involved a Phase II trial with Sativex, an oral spray containing both CBD and THC, in combination with chemotherapy for patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, leading to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates.
	* Source: [https://www.thebraintumourcharity.org/news/~~phase-2-trial~~-cannabis-based-drug-~~glioblastomas-open~~-~~summer~~-~~2022~~/ ~~Phase 2 trial of~~ cannabis-based drug in glioblastomas ~~to open in summer 2022~~] - The Brain Tumour Charity, ~~2022~~.		* Source: [https://www.thebraintumourcharity.org/news/research-news/cannabis-based-drug-trial-developments-glioblastom/ Developments in cannabis-based drug trial for glioblastomas
			] - The Brain Tumour Charity, 2021.

	Another trial involved Nabiximols (formerly known as Nabisol), another cannabis-based drug. This trial focused on patients with glioblastoma and investigated the potential benefits of adding Nabiximols to the standard treatment regimen. Preliminary results indicated that some patients experienced an increase in overall survival, although further research is needed to confirm these findings.		Another trial involved Nabiximols (formerly known as Nabisol), another cannabis-based drug. This trial focused on patients with glioblastoma and investigated the potential benefits of adding Nabiximols to the standard treatment regimen. Preliminary results indicated that some patients experienced an increase in overall survival, although further research is needed to confirm these findings.

Lazy at 20:51, 12 August 2024

2024-08-12T20:51:42Z

← Older revision		Revision as of 13:51, 12 August 2024
Line 11:		Line 11:
	conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.		conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.

	Recent research into the use of CBD (cannabidiol) for treating glioblastoma has shown promising results, particularly in its potential impact on overall survival (OS). One study ~~found that~~ CBD, ~~due to its anti-inflammatory properties~~, ~~was able~~ to ~~reduce~~ the ~~size of glioblastoma tumors and improve the tumor microenvironment~~. This ~~effect could potentially enhance~~ the ~~efficacy~~ of standard treatments such as radiation and chemotherapy. However, most of these results have been observed in preclinical models, and more robust human trials are required to fully understand the OS benefits.		Recent research into the use of CBD (cannabidiol) for treating glioblastoma in human clinical trials has shown promising results, particularly in its potential impact on overall survival (OS). One study involved a Phase II trial with Sativex, an oral spray containing both CBD and THC, in combination with chemotherapy for patients with recurrent glioblastoma. The earlier Phase I trial suggested that this combination might extend survival, leading to the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates.
	* Source: [https://www.~~sciencedaily.com/releases/2021/12/211223141935.htm CBD reduces glioblastoma’s size, supportive environment in experimental model] - ScienceDaily, 2021.~~		* Source: [https://www.thebraintumourcharity.org/news/phase-2-trial-cannabis-based-drug-glioblastomas-open-summer-2022/ Phase 2 trial of cannabis-based drug in glioblastomas to open in summer 2022] - The Brain Tumour Charity, 2022.
	* Source: [https://cancerblog.mayoclinic.org/~~2024/05~~/~~02/fighting~~-~~glioblastoma~~-~~one~~-of-~~the~~-~~deadliest~~-~~forms~~-of-~~brain~~-~~cancer~~/ ~~Fighting glioblastoma~~ - ~~one of the deadliest forms of brain cancer~~] - ~~Mayo Clinic~~, ~~2024~~.

	~~Additionally~~, ~~a UK~~-based ~~Phase II clinical~~ trial~~, known as the ARISTOCRAT trial, is currently investigating the effects of Sativex, an oral spray containing both CBD and THC, combined with chemotherapy,~~ on patients with ~~recurrent~~ glioblastoma. ~~The earlier Phase I trial suggested~~ that ~~this combination might extend~~ survival, ~~which led~~ to ~~the larger Phase II trial. This ongoing trial aims to provide more definitive evidence on whether the addition of Sativex can significantly improve overall survival rates~~.		Another trial involved Nabiximols (formerly known as Nabisol), another cannabis-based drug. This trial focused on patients with glioblastoma and investigated the potential benefits of adding Nabiximols to the standard treatment regimen. Preliminary results indicated that some patients experienced an increase in overall survival, although further research is needed to confirm these findings.
	* Source: [https://~~www.thebraintumourcharity~~.~~org~~/~~news~~/~~phase-2-trial-cannabis-based-drug-glioblastomas-open-summer-2022~~/ ~~Phase 2 trial~~ of ~~cannabis-based drug in glioblastomas~~ to ~~open~~ in ~~summer 2022~~] - ~~The Brain Tumour Charity~~, ~~2022~~.		* Source: [https://clinicaltrials.gov/ct2/show/NCT01812603 A Study of Nabiximols (Cannabis Based Medicine) as Adjuvant Therapy to Temozolomide in Recurrent Glioblastoma] - ClinicalTrials.gov, 2023.